These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35073217)

  • 1. Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids.
    Sasaki T; Hirakawa Y; Yamairi F; Kurita T; Murahashi K; Nishimura H; Iwazaki N; Yasuhara H; Tateoka T; Ohta T; Obika S; Kotera J
    Nucleic Acid Ther; 2022 Jun; 32(3):177-184. PubMed ID: 35073217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanidine bridged nucleic acid (GuNA): an effect of a cationic bridged nucleic acid on DNA binding affinity.
    Shrestha AR; Kotobuki Y; Hari Y; Obika S
    Chem Commun (Camb); 2014 Jan; 50(5):575-7. PubMed ID: 24270219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids.
    Shimo T; Nakatsuji Y; Tachibana K; Obika S
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
    Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and properties of a novel modified nucleic acid, 2'-N-methanesulfonyl-2'-amino-locked nucleic acid.
    Sawamoto H; Sasaki T; Takegawa-Araki T; Utsugi M; Furukawa H; Hirakawa Y; Yamairi F; Kurita T; Murahashi K; Yamada K; Ohta T; Kumagai S; Takemiya A; Obika S; Kotera J
    Bioorg Med Chem Lett; 2023 May; 88():129289. PubMed ID: 37068560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
    Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
    Laxton C; Brady K; Moschos S; Turnpenny P; Rawal J; Pryde DC; Sidders B; Corbau R; Pickford C; Murray EJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3105-14. PubMed ID: 21502629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals.
    Seth PP; Jazayeri A; Yu J; Allerson CR; Bhat B; Swayze EE
    Mol Ther Nucleic Acids; 2012 Sep; 1(10):e47. PubMed ID: 23344239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression.
    Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M
    Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
    Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
    Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
    Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
    Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.
    Kakiuchi-Kiyota S; Koza-Taylor PH; Mantena SR; Nelms LF; Enayetallah AE; Hollingshead BD; Burdick AD; Reed LA; Warneke JA; Whiteley LO; Ryan AM; Mathialagan N
    Toxicol Sci; 2014 Mar; 138(1):234-48. PubMed ID: 24336348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin-2.
    Horie S; Suzuki Y; Yamamoto T; Obika S; Mohri K; Kiyota C; Ren Q; Warashina S; Wada Y; Watanabe Y; Mukai H; Sato Y
    Cancer Sci; 2023 Sep; 114(9):3740-3749. PubMed ID: 37430466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.
    Nishina T; Numata J; Nishina K; Yoshida-Tanaka K; Nitta K; Piao W; Iwata R; Ito S; Kuwahara H; Wada T; Mizusawa H; Yokota T
    Mol Ther Nucleic Acids; 2015 Jan; 4(1):e220. PubMed ID: 25584900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
    Hara RI; Yoshioka K; Yokota T
    Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facile synthesis and fundamental properties of an N-methylguanidine-bridged nucleic acid (GuNA[NMe]).
    Horie N; Kumagai S; Kotobuki Y; Yamaguchi T; Obika S
    Org Biomol Chem; 2018 Sep; 16(35):6531-6536. PubMed ID: 30160290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.